Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • Pharma cos facing pricing pressure in US: PhillipCap

    • USFDA warning: Have 15 days to respond, says DRL CFO

    • Elepsia drug more relevant to Sun Pharma: Phillipcap

    • Plan to revamp systems as per FDA expectations: Dr Reddy's

    • Business mix change drove gross margins higher: Dr Reddy's

    • See growth over base of last year: Dr Reddy's CEO

    • Eye significant growth in acquired UCB drugs: Dr Reddy's

    • See Rs 400cr increase in top line over next few yrs: Hetero

    • Russia's impact not fully played out in Q3: Dr Reddy's

    • Core generics, API biz to drive FY16 growth: Dr Reddy's

    • Sun's margins may reduce to 30-32% post merger: Surajit Pal

    • Ranbaxy loses Valcyte exclusivity: An analysis

    • Likely to file 2 NDAs worth $100 m each soon: Dr Reddy's

    • DRL-GSK generic formulations deal under review: PharmAsia

    • R&D spend to go up by 9-10% in next few years: Dr Reddy‘s

    • Dr Reddy's EBITDA up on product launches: CFO

      Umang Vohra, executive VP and CFO, Dr Reddy‘s Laboratories explains to CNBC-TV18 that product launches have caused the surge in the pharma giant's quarterly EBITDA.

    • US, Russia & API boost Dr Reddy's as busy year looms

      GV Prasad VC & CEO, Dr Reddy Laboratories explains to CNBC-TV18 that the reason for company‘s good performance for the quarter is the robust growth in the US, Russia and the API business

    • Have many significant product launches lined up: Dr Reddy's

      Dr Reddy’s also has slew of significant new launches lined-up ahead. It would also be launching a biosimilar product every year beginning with the Indian market. These products are expected to drive company's near-term growth.

    • Business from Russia, US markets add to Dr Reddy's coffers

      G V Prasad, VC & CEO, Dr Reddy's Laboratories tells CNBC-TV18 that North America, Russia and the Pharmaceuticals Services and Active Ingredients (PSAI) segment led to the stupendous growth in the business.

    • JB Chem to use major sale proceeds to reward shareholders

      Leading global pharmaceutical company JB Chemical has sold its prescription business to Dr Reddy's for USD 35 million. In an exclusive interview with CNBC-TV18, the company’s president, Pranabh Mody says a significant part of the cash earned from the sell will be used to reward shareholders.

    • Product launch, US sales to aid growth in H2FY12: DRL

      In an interview with CNBC-TV18, GV Prasad, vice-chairman & CEO of DRL spoke about the company's quarterly performance and future plans.

    • To improve market share, position in Germany: Dr Reddy's

      GV Prasad, Vice Chairman and CEO, Dr Reddys Laboratories in an interview with CNBC-TV18 spoke about the quarterly numbers of the company and the road ahead.

    • Unsure of how biz will shape up in German mkt: Dr Reddy's

    • What is Lupin's acquisition agenda for the future?

    • Ranbaxy, Merck call off anti-infectives deal

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347